Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 4 | |
| UDC.journalTitle | Antimicrobial Agents and Chemotherapy | |
| UDC.volume | 70 | |
| dc.contributor.author | Rodríguez-Pallares, Salud | |
| dc.contributor.author | Outeda-García, Michelle | |
| dc.contributor.author | Lence, Emilio | |
| dc.contributor.author | Rodríguez-Coello, Arianna | |
| dc.contributor.author | González-Pinto, Lucía | |
| dc.contributor.author | Guijarro-Sánchez, Paula | |
| dc.contributor.author | Báez-Barroso, Gabriela Alejandra | |
| dc.contributor.author | Blanco Martín, Tania | |
| dc.contributor.author | Vázquez-Ucha, Juan Carlos | |
| dc.contributor.author | Llanos, Agustina | |
| dc.contributor.author | Sannio, Filomena | |
| dc.contributor.author | Docquier, Jean-Denis | |
| dc.contributor.author | Hawser, Stephen | |
| dc.contributor.author | Zalacain, Magdalena | |
| dc.contributor.author | Lemonnier, Marc | |
| dc.contributor.author | González-Bello, Concepción | |
| dc.contributor.author | Bou, Germán | |
| dc.contributor.author | Beceiro Casas, Alejandro | |
| dc.contributor.author | Arca-Suárez, Jorge | |
| dc.date.accessioned | 2026-04-20T05:54:03Z | |
| dc.date.available | 2026-04-20T05:54:03Z | |
| dc.date.issued | 2026-02-19 | |
| dc.description.abstract | [Abstract] Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant (Kd ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH-F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections. | |
| dc.description.sponsorship | This research was supported by Antabio through a service agreement with Fundación Publica Galega de Investigación Biomédica INIBIC. The study was supported by the Instituto de Salud Carlos III (ISCIII projects PI23/00851, PI22/01212, PI21/00704, and PI20/01212) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00055), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016, and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by Axencia Galega de Innovacion (GAIN), Conselleria de Innovacion, Conselleria de Emprego e Industria through “Proxectos de excelencia” (IN607D 2021/12 to A.B. and IN607D 2024/08 to J.A.-S.), and ‘’Axudas para a consolidación de grupos de investigación que pola súa produción científica e a súa actividade de I+D constitúan unha referencia no Sistema galego de I+D+I’’ (IN607A 2024/09 to G.B.). The study was also funded by the Spanish State Agency of Research (PID2022-136963OB-I00/AEI/10.13039/501100011033, C.G.-B.), the Xunta de Galicia [ED431C 2025/05 and Centro singular de investigación de Galicia accreditation 2023–2027 (ED431G 2023/03), C.G.-B.], and the European Regional Development Fund (ERDF). S.R.-P. was financially supported by the Río Hortega Program (ISCIII, CM23/00104). M.O.-G. was financially supported by IN606A 2023/023. A.R.-C. was supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI24/00178). L.G.-P. was financially supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI23/00074). G.A.B.-B. was financially supported by IN606A-2024/033 (Xunta de Galicia). T.B.-M. was financially supported by the Río Hortega Program (ISCIII, CM23/00095). J.C.V.-U. was financially supported by IN606B-2022/009 (Xunta de Galicia). J.A.-S. was financially supported by the Juan Rodés Program (ISCIII, JR21/00026). J.-D.D. was supported in part by the Italian Ministry of University and Research and the European Union (“Unione Europea—Next Generation EU, Missione 4 Componente 2 Inv. 1.5 CUP_B63C22001400007) in the frame of the PNRR PE-13 (“Piano Nazionale di Ripresa e Resilienza, Partenariato Esteso 13, Malattie infettive emergenti”) INF-ACT project (One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases). This work was also supported by the Fundación Pública Galega de Investigación Biomédica INIBIC, which provided financial support for the final publication of the article. | |
| dc.identifier.citation | Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, Báez-Barroso GA, Blanco-Martín T, Vázquez-Ucha JC, Llanos A, Sannio F, Docquier J-D, Morrisey I, Hawser S, Zalacain M, Lemonnier M, González-Bello C, Bou G, Beceiro A, Arca-Suárez J. Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). Antimicrob Agents Chemother. 2026 Apr;70(4):e0169125 | |
| dc.identifier.doi | 10.1128/AAC.01691-25 | |
| dc.identifier.issn | 1098-6596 | |
| dc.identifier.uri | https://hdl.handle.net/2183/48033 | |
| dc.language.iso | eng | |
| dc.publisher | American Society for Microbiology | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01212/ES/Inhibidores de carbapenemasas: actividad frente a Enterobacterales productores de carbapenemasas, mecanismos e impacto en la evolución de la resistencia antimicrobiana (PROTECT)/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI21%2F00704/ES/VACUNAS AUXOTROFAS ORALES PARA LA ERRADICACION DE BACTERIAS INTESTINALES: COLONIZACIÓN INTESTINAL POR KLEBSIELLA PNEUMONIAE MULTIRRESISTENTE COMO MODELO/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F01212/ES/DESARROLLO Y EVALUACION DE NUEVAS MOLECULAS ANTIMICROBIANAS DIRIGIDAS A PATOGENOS MULTIRRESISTENTES (INHIBIDORES DE ß-LACTAMASAS Y CONJUGADOS TETRACICLINAS-SIDEROFOROS). ESTUDIO NACIONAL ACINETOBACTER SPP./ | |
| dc.relation.projectID | Xunta de Galicia; IN607D 2021/1 | |
| dc.relation.projectID | Xunta de Galicia; IN607D 2024/08 | |
| dc.relation.uri | https://doi.org/10.1128/AAC.01691-25 | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | ANT3310 | |
| dc.subject | Acinetobacter baumannii | |
| dc.subject | OXA-23 | |
| dc.subject | Carbapenem resistance | |
| dc.subject | Carbapenems | |
| dc.subject | Pilabactam | |
| dc.subject | β-lactamase | |
| dc.subject | β-lactamase inhibitors | |
| dc.title | Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310) | |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |

